Enhabit (EHAB) Competitors

$8.60
+0.35 (+4.24%)
(As of 02:27 PM ET)

EHAB vs. AVAH, AHCO, ADUS, PEPG, ZIMV, TBPH, FULC, LXEO, CRBP, and BMEA

Should you be buying Enhabit stock or one of its competitors? The main competitors of Enhabit include Aveanna Healthcare (AVAH), AdaptHealth (AHCO), Addus HomeCare (ADUS), PepGen (PEPG), ZimVie (ZIMV), Theravance Biopharma (TBPH), Fulcrum Therapeutics (FULC), Lexeo Therapeutics (LXEO), Corbus Pharmaceuticals (CRBP), and Biomea Fusion (BMEA). These companies are all part of the "medical" sector.

Enhabit vs.

Aveanna Healthcare (NASDAQ:AVAH) and Enhabit (NYSE:EHAB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Aveanna Healthcare has a net margin of -5.92% compared to Aveanna Healthcare's net margin of -7.95%. Aveanna Healthcare's return on equity of 1.43% beat Enhabit's return on equity.

Company Net Margins Return on Equity Return on Assets
Aveanna Healthcare-5.92% N/A -1.76%
Enhabit -7.95%1.43%0.69%

Aveanna Healthcare has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500. Comparatively, Enhabit has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500.

Enhabit has lower revenue, but higher earnings than Aveanna Healthcare. Enhabit is trading at a lower price-to-earnings ratio than Aveanna Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aveanna Healthcare$1.90B0.29-$134.52M-$0.60-4.77
Enhabit$1.05B0.41-$80.50M-$1.66-5.18

Aveanna Healthcare received 21 more outperform votes than Enhabit when rated by MarketBeat users. Likewise, 38.71% of users gave Aveanna Healthcare an outperform vote while only 12.00% of users gave Enhabit an outperform vote.

CompanyUnderperformOutperform
Aveanna HealthcareOutperform Votes
24
38.71%
Underperform Votes
38
61.29%
EnhabitOutperform Votes
3
12.00%
Underperform Votes
22
88.00%

Aveanna Healthcare presently has a consensus price target of $1.80, indicating a potential downside of 37.06%. Enhabit has a consensus price target of $10.13, indicating a potential upside of 17.73%. Given Aveanna Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Enhabit is more favorable than Aveanna Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aveanna Healthcare
3 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.60
Enhabit
1 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.88

In the previous week, Enhabit had 23 more articles in the media than Aveanna Healthcare. MarketBeat recorded 25 mentions for Enhabit and 2 mentions for Aveanna Healthcare. Enhabit's average media sentiment score of 1.23 beat Aveanna Healthcare's score of 0.71 indicating that Aveanna Healthcare is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aveanna Healthcare
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Enhabit
7 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

88.0% of Aveanna Healthcare shares are held by institutional investors. 7.8% of Aveanna Healthcare shares are held by insiders. Comparatively, 1.9% of Enhabit shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Aveanna Healthcare beats Enhabit on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EHAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EHAB vs. The Competition

MetricEnhabitHome health care services IndustryMedical SectorNYSE Exchange
Market Cap$431.29M$2.84B$4.95B$17.96B
Dividend YieldN/A0.28%44.82%3.43%
P/E Ratio-5.1810.98126.0223.62
Price / Sales0.411.162,473.6510.85
Price / Cash3.1814.2032.2315.96
Price / Book0.623.064.985.04
Net Income-$80.50M-$57.02M$101.88M$973.44M
7 Day Performance-0.46%1.90%2.82%2.64%
1 Month Performance-16.10%3.63%6.66%7.51%
1 Year Performance-27.67%20.51%8.47%25.06%

Enhabit Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVAH
Aveanna Healthcare
0.2192 of 5 stars
$2.57
+3.6%
$1.80
-30.0%
+116.3%$494.42M$1.90B-4.2833,500Positive News
AHCO
AdaptHealth
3.0462 of 5 stars
$9.83
+3.5%
$12.42
+26.3%
-9.6%$1.26B$3.24B-1.8710,700Gap Up
ADUS
Addus HomeCare
4.5515 of 5 stars
$109.86
-0.6%
$108.57
-1.2%
+24.9%$1.80B$1.06B27.2634,846
PEPG
PepGen
1.887 of 5 stars
$13.99
+5.2%
$24.67
+76.3%
-8.4%$453.14MN/A-4.2364Insider Selling
Analyst Revision
News Coverage
Gap Up
ZIMV
ZimVie
0.2802 of 5 stars
$16.68
-0.8%
$16.00
-4.1%
+59.4%$455.20M$457.43M-1.192,600
TBPH
Theravance Biopharma
1.9537 of 5 stars
$9.39
-2.0%
$20.50
+118.3%
-17.1%$455.98M$57.42M-9.68359
FULC
Fulcrum Therapeutics
2.7436 of 5 stars
$7.91
+7.6%
$14.67
+85.4%
+132.3%$456.83M$2.81M-5.0176Analyst Forecast
Gap Up
LXEO
Lexeo Therapeutics
2.6924 of 5 stars
$13.97
+3.0%
$20.80
+48.9%
N/A$446.73M$650,000.00-0.6358
CRBP
Corbus Pharmaceuticals
4.2383 of 5 stars
$42.99
+0.3%
$61.00
+41.9%
+314.7%$459.43M$880,000.00-6.1819Analyst Upgrade
BMEA
Biomea Fusion
1.7257 of 5 stars
$12.37
+8.0%
$53.25
+330.5%
-61.4%$444.58MN/A-3.46103Positive News
Gap Up

Related Companies and Tools

This page (NYSE:EHAB) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners